{"anticipatedPostingDate":"2010-05","classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"200","value":"107"},{"groupId":"OG001","lowerLimit":"69","upperLimit":"130","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Median number of days from first date of treatment to date of disease progression (appearance of new metastatic lesions or objective tumor progression). Defined by computated tomography (CT) imaging based on Response Evaluation Criteria In Solid Tumors (RECIST): Progressive Disease (PD) \\> or = 20% increase in sum of all target or any new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\\^2 and fludarabine 25 mg/m\\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \\* 10\\^7 kg) and no total body irradiation.","id":"OG000","title":"No Total Body Irradiation"},{"description":"This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\\^2 and fludarabine 25 mg/m\\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \\* 10\\^7 kg) and total body irradiation (200 Gy on Day 1 preceding natural killer cell infusion).","id":"OG001","title":"Total Body Irradiation"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of first treatment to disease progression","title":"Median Number of Days to Progression","type":"SECONDARY","unitOfMeasure":"Days"}